China Pharma Begins First Work On Producing H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's Hualan Biological Engineering says it has begun producing a solution aimed at creating a vaccine against the H1N1 flu virus. The company said it began work just hours after receiving seed viruses from the World Health Organization. Hualan is the only company certified in China to produce a pandemic vaccine, but 10 makers of seasonal-flu vaccines also are expected to receive the seed viruses. The head of SFDA's biology production office said the first batch of vaccines is expected to be produced as early as late July. The WHO has yet to decide whether the H1N1 flu virus is seasonal or pandemic. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.